Press Releases Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Market Closed - Nasdaq Stockholm Other stock markets 11:29:33 2024-05-17 am EDT			5-day change	1st Jan Change
96.6 ^SEK	+0.62%		+3.87%	+7.33%

May. 07	Infant Bacterial Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Feb. 08	Infant Bacterial Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annual General Meeting of Infant Bacterial Therapeutics	May. 08	AQ
Infant Bacterial Therapeutics () : Interim report January 1 - March 31, 2024	May. 07	PU
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – March 31, 2024	May. 07	AQ
Infant Bacterial Therapeutics : Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics' Phase 3 Study	Apr. 04	PU
Major Milestone Achieved - Last Patient Enrolled in Infant Bacterial Therapeutics’ Phase 3 Study	Apr. 04	AQ
Notice of Annual General Meeting of Infant Bacterial Therapeutics	Apr. 03	AQ
Infant Bacterial Therapeutics AB publishes the Annual Report for 2023	Mar. 25	AQ
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023	Feb. 08	AQ
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2023	Nov. 10	AQ
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2024	23-10-24	AQ
Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023	23-08-25	GL
New number of shares and votes in IBT	23-07-31	GL
New number of shares and votes in IBT	23-07-31	AQ
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation	23-07-04	AQ
IBT announces outcome of its rights issue	23-07-04	GL
Additional Infant Bacterial Therapeutics product receives FDA orphan drug designation	23-07-03	GL
The futility analysis for IBT’s Connection Study positive	23-06-21	GL
The futility analysis for IBT’s Connection Study positive	23-06-21	AQ
IBT continues to recruit prematurely born infants to The Connection Study following a planned safety analysis.	23-06-21	GL
New patent for Infant Bacterial Therapeutics has been approved in Europe	23-06-15	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Infant Bacterial Therapeutics AB

Equities

IBT B

SE0008015259

Press Releases

Filters